Top Atlanta, GA Health Tech Companies With Best Stability & Growth (232)

Strong Hiring & Retention: Hiring and headcount are expanding, with disclosures of 15,000+ global employees, thousands of new hires, and third‑party estimates indicating continued workforce growth. Available evidence also points to active internal mobility and a recent increase in active job postings.

Market Expansion: Geographic and client footprints are broadening, with 40+ offices and 1,700+ customers across 170+ countries alongside concrete investments in new and expanded locations such as Hyderabad and Kingston. These moves indicate scaling delivery capacity in major capability centers and new regions.

Innovation-Driven Growth: The offering mix is shifting toward AI, data, technology, and platforms, including proprietary solutions and product capabilities. Strategic moves such as Salesforce-focused acquisitions and collaborations, plus a Tulip solution partnership, extend capabilities beyond traditional consulting.

Strong Revenue Growth: Optum’s consolidated revenue expanded from $253.0B in 2024 to $270.6B in 2025, indicating continued top-line growth. Multi‑year reporting also highlights ongoing increases at the consolidated level even as segment performance diverges.

Diversified Revenue Streams: Performance is spread across three businesses, with Optum Rx delivering substantial gains, Optum Insight growing modestly, and Optum Health contracting. This mix shows pharmacy and technology services helping sustain overall scale despite softness in care delivery.

Cost & Operational Efficiency: Operating performance improved in 2026 as Optum’s operating income rose year over year to about $4B in Q2 alongside reported gains in technology and clinical operations. UnitedHealth also raised its 2026 adjusted EPS outlook, signaling confidence in execution.

Strong Revenue Growth: Reported revenue has been rising at a double‑digit pace across fiscal 2025 and the first half of 2026, with both Q1 and Q2 showing solid year‑over‑year increases. Management also raised full‑year 2026 revenue guidance, indicating confidence in continued expansion.

Profitability: Profitability is strong, with adjusted EBITDA growing year over year and margins holding in the low‑40s through fiscal 2025 and recent quarters. The company also reported positive net income and healthy cash generation.

Customer Loyalty & Retention: Net revenue retention remained expansionary and the number of larger clients increased year over year. Subscription revenue grew faster than total revenue in recent periods, suggesting deeper adoption within the existing base.

Strong Revenue Growth: Repeated inclusion on the Inc. 5000 list and an Inc. profile noting 27% three-year growth for 2026 indicate sustained top-line expansion.

Market Expansion: Acquisitions in 2023 (ABA Therapy Billing & Insurance Services) and 2025 (Joshin), plus the addition of a Chief Revenue Officer and an SVP of Enterprise Sales, point to expansion across providers, disability support, and enterprise channels.

Innovation-Driven Growth: New AI-enabled capabilities for behavioral-health workflows and analytics recognition suggest product momentum that supports continued scaling.

Market Expansion: Operations have expanded from 3 to 14 and then 20+ states, with 8,800+ patients served and 17,700+ completed service requests by April 2025. Ongoing recruitment of transportation partners across Georgia and South Carolina underscores continued footprint growth.

Product Line Growth: Offerings now span transportation, interpretation, prescription delivery, post-procedure care, home health, and telemedicine within an integrated coordination platform. This broadened scope indicates expansion beyond a pure NEMT broker into a wider patient-access solution.

Investor Backing & Capital Strength: External sources cite roughly mid–single-digit millions raised across multiple seed rounds, including an oversubscribed Seed-3 in early 2023. Participation in programs with institutions such as Morgan Stanley and Mastercard Start Path signals ongoing investor support.

Strong Market Position & Advantage: Takeda is consistently placed among the global top 15–20 by revenue and is a clear category leader in GI/IBD, plasma-derived therapies, and dengue vaccines with broad international authorizations and WHO support. Subcutaneous ENTYVIO and new oncology approvals like FRUZAQLA broaden real‑world use and extend reach.

Profitability: Reported FY2025 operating profit rose 19.3% year over year and EPS nearly doubled despite a slight revenue decline, supported by lower amortization and restructuring expense. Core profitability remained broadly stable as Growth & Launch Products expanded their share.

Future-Ready Strategy: Management is investing through FY2026 to convert a late‑stage pipeline (e.g., oveporexton, rusfertide, zasocitinib) into multiple launches, with Growth & Launch Products prioritized as near‑term engines. A multi‑year transformation and efficiency program targeting significant savings by FY2028 is intended to fund launches and strengthen competitiveness.

Strong Market Position & Advantage: Evidence indicates Milliman holds a leading actuarial position with insurers and pensions, reinforced by top industry rankings and widely cited benchmarks. Proprietary platforms used globally further underscore durable competitive advantage.

Product Line Growth: Feedback suggests the firm is expanding offerings and distribution, exemplified by healthcare‑inflation ETFs and growing adoption/awards for its actuarial software and analytics. Additional regulatory approvals for telematics risk scores point to rising product traction.

Market Expansion: Signals such as rising FRM assets under management, new client services in additional geographies, and targeted office expansions suggest continued reach across segments and regions. Directionally increasing headcount further supports expanding capacity.

Strong Market Position & Advantage: Evidence suggests MEDITECH holds a top-three position in U.S. inpatient EHRs, with recognized leadership in community/small hospitals and in Canada. Industry accolades like repeated Best in KLAS for Expanse in small-acute segments reinforce standing in its core markets.

Market Expansion: Recent enterprise deployments (such as HCA go-live waves), continuing community/rural wins via MaaS, and new international go-lives point to selective expansion. Coverage notes active participation in global contracting cycles and growing cloud-delivered implementations.

Customer Loyalty & Retention: Independent tracking indicates many legacy customers are migrating to Expanse rather than switching vendors. Continued segment recognition aligns with durable satisfaction in core community tiers.

Strong Market Position & Advantage: Roche is the global leader in in‑vitro diagnostics and remains a top‑tier biopharma with a significant oncology footprint. The dual Pharmaceuticals–Diagnostics model is a strategic differentiator at scale.

Strong Revenue Growth: Group sales rose 7% at constant exchange rates in 2025 and 6% at CER in Q1 2026, with both divisions contributing. Guidance for 2026 indicates continued mid–single‑digit CER growth.

Profitability: Profitability improved in 2025 alongside sales, with higher IFRS net income and core EPS growth. Management pointed to capacity to keep investing while rewarding shareholders.

Strong Market Position & Advantage: The company is described as the global leader in dialysis services and products, reinforced by a large clinic footprint and dominance in key product categories. A vertically integrated model across care delivery and manufacturing underpins scale advantages.

Strong Revenue Growth: Recent periods show consistent organic growth across segments with accelerating momentum and confirmed positive guidance. Expansion in value-based care and pricing, alongside steady treatment volumes, supports this trajectory.

Cost & Operational Efficiency: Transformation programs are delivering substantial savings that are expanding margins and improving profitability. Operational initiatives and portfolio optimization are described as driving a structural earnings reset.